CClinicalTrials.gg
Status unknownNCT01584271Updated Jul 9, 2013

Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)

A Phase 2 interventional study of Natural Ear Comfort(TM), a botanical ear drops product in Acute Otitis Externa, sponsored by Assuta Hospital Systems. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-07-09.

Sponsored by Assuta Hospital Systems · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Phase II 3 arm double blinded clinical study, to evaluate pain killing and healing time of Botanical Ear Drops, Ear Comfort™, in Severe External Ear Infection (AOE) patients in comparison to Dex-Otic® and Otidin®.

Study Outcome (hypothesis): if Ear Comfort™ proves to perform as well as Dex-Otic, then ENT's and family doctors will have a botanical non-antibiotic product that does not promote the formation of antibiotic-resistant infections and may be given to anti-biotics sensitive patients.

Ear comfort™ is pharmacologically stable for at least 3 years on the shelves.

Read the detailed description

Severe External Ear Infection (AOE) also known as Swimmer's ear, is an abundant microbiological contamination disease of the outer ear canal. It causes severe pains and accumulation of fluids in the ear. In some cases it may compromise the hearing. Swimming in contaminated water or cleaning the ear with a hard subject are only two examples of what may cause AOE. The main Pathogenes causing the disease are Gram negative of which Pseudomonas aeruginosa is the most abundant. Occasionally it is a fungoid contamination with Aspergillus Niger being the most abundant.

02

Conditions studied

  • Acute Otitis Externa

Browse trials for

Keywords

  • AOE
  • Ear Comfort
  • Dex Otic
  • Otidin
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with AOE.
  • AOE patient determined by ear canal obstruction, exudates and pain.
  • Males and Females between 18 and 65 years of age.
  • Patients willing to refrain from using any ear drops products for the entire duration of the study. - - Subjects are willing to use the full 4 steps protocol
  • Written informed consent has been obtained.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or sensitivity to Chamomile extract or essential oils.
  • Injury to tympanic membrane.
  • Medical or psychiatric conditions that affect the patient's ability to give informed consent, or complete the study.
  • Pregnant or lactating females.
  • Use of ear drops or antibiotic or analgesic medications within the last 4 weeks prior to enrolment to the study.
  • Other known diseases, including severe allergy, chronic liver or kidney disease, malignancy or contagious diseases, such as HIV or hepatitis.
  • Alcohol or drug abuse, according to assessment by the investigator.
  • Participation in other clinical trial within the last 30 days.
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    2 Dex-Otic ear drops

    Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It

    Device: Natural Ear Comfort(TM), a botanical ear drops product

  • Experimental
    3 Ear Comfort(TM) ear drops

    Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.

    Device: Natural Ear Comfort(TM), a botanical ear drops product

  • Active comparator
    1 Otidin(R) ear drops

    Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.

    Device: Natural Ear Comfort(TM), a botanical ear drops product

Interventions

  • DeviceNatural Ear Comfort(TM), a botanical ear drops product

    Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant. Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units. Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water. Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.

    Also known as: 1 local pain killer, 2 antibiotics & steroid anti-inflamatory ear drops, 3 Ear Comfort(TM) botanical ear drops

05

What researchers measure

Primary outcomes

  1. Ear Comfort(TM) kills pain in AOE patients within how many hours?

    Comparing Ear Comfort(TM) botanical ear drops performance in killing pain in AOE patients to Dex-Otic and Otidin Will be measured by Pain Scores on the Visual Analog Scale. The patients will score their pains on a patient's diary document. A professional medical statitician expert will make the anlysis.

    Time frame: 12 months

Secondary outcomes

  1. Does Ear Comfort(TM) heal the inflamation in AOE patients?

    Performance of Ear Comfort(TM) ear drops, Dex-Otic and Otidin in healing AOE patients ear will be measured by: - reducing microbiological load, patient's compliance and ENT expert/s check of the year during the treatment period and 7 days after stopping the treatment.

    Time frame: 12 months

06

Study locations

1 of 1 sites recruiting
  • "Maccabi" Clinic
    Gedera, Israel
    Recruiting
07

Registry details

Key details

Study ID
NCT01584271
Lead sponsor
Assuta Hospital Systems
Responsible party
Sponsor
First posted
Apr 24, 2012
Start date
Jul 2011
Primary completion
Aug 2013 (estimated)
Completion
Dec 2013 (estimated)
Last update
Jul 9, 2013

Study contacts

Dan Guttman, MD
principal investigator · Maccabi Healthcare Services, Israel

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion